Cargando…

Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial

BACKGROUND: The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic Alzheimer’s disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal cognitive aging and dementia, which is easy to convert to AD dementia. It is an ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guan-Qun, Sheng, Can, Li, Yu-Xia, Yu, Yang, Wang, Xiao-Ni, Sun, Yu, Li, Hong-Yan, Li, Xuan-Yu, Xie, Yun-Yan, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866435/
https://www.ncbi.nlm.nih.gov/pubmed/27176479
http://dx.doi.org/10.1186/s12883-016-0587-2
_version_ 1782431921097146368
author Chen, Guan-Qun
Sheng, Can
Li, Yu-Xia
Yu, Yang
Wang, Xiao-Ni
Sun, Yu
Li, Hong-Yan
Li, Xuan-Yu
Xie, Yun-Yan
Han, Ying
author_facet Chen, Guan-Qun
Sheng, Can
Li, Yu-Xia
Yu, Yang
Wang, Xiao-Ni
Sun, Yu
Li, Hong-Yan
Li, Xuan-Yu
Xie, Yun-Yan
Han, Ying
author_sort Chen, Guan-Qun
collection PubMed
description BACKGROUND: The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic Alzheimer’s disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal cognitive aging and dementia, which is easy to convert to AD dementia. It is an urgent problem in the field of cognitive neuroscience to reveal the conversion of aMCI-ε4 to AD. Based on our preliminary work, we will study the neuroimaging features in the special group of aMCI-ε4 with multi-modality magnetic resonance imaging (structural MRI, resting state-fMRI and diffusion tensor imaging) longitudinally. METHODS/DESIGN: In this study, 200 right-handed subjects who are diagnosed as aMCI with APOE-ε4 will be recruited at the memory clinic of the Neurology Department, XuanWu Hospital, Capital Medical University, Beijing, China. All subjects will undergo the neuroimaging and neuropsychological evaluation at a 1 year-interval for 3 years. The primary outcome measures are 1) Microstructural alterations revealed with multimodal MRI scans including structure MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor imaging (DTI); 2) neuropsychological evaluation, including the World Health Organization-University of California-LosAngeles Auditory Verbal Learning Test (WHO-UCLA AVLT), Addenbrook’s cognitive examination-revised (ACE-R), mini-mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating scale (CDR). DISCUSSION: This study is to find out the neuroimaging biomarker and the changing laws of the marker during the progress of aMCI-ε4 to AD, and the final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of AD. TRIAL REGISTRATION: This study has been registered to ClinicalTrials.gov (NCT02225964, https://www.clinicaltrials.gov/) in August 24, 2014.
format Online
Article
Text
id pubmed-4866435
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48664352016-05-14 Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial Chen, Guan-Qun Sheng, Can Li, Yu-Xia Yu, Yang Wang, Xiao-Ni Sun, Yu Li, Hong-Yan Li, Xuan-Yu Xie, Yun-Yan Han, Ying BMC Neurol Study Protocol BACKGROUND: The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic Alzheimer’s disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal cognitive aging and dementia, which is easy to convert to AD dementia. It is an urgent problem in the field of cognitive neuroscience to reveal the conversion of aMCI-ε4 to AD. Based on our preliminary work, we will study the neuroimaging features in the special group of aMCI-ε4 with multi-modality magnetic resonance imaging (structural MRI, resting state-fMRI and diffusion tensor imaging) longitudinally. METHODS/DESIGN: In this study, 200 right-handed subjects who are diagnosed as aMCI with APOE-ε4 will be recruited at the memory clinic of the Neurology Department, XuanWu Hospital, Capital Medical University, Beijing, China. All subjects will undergo the neuroimaging and neuropsychological evaluation at a 1 year-interval for 3 years. The primary outcome measures are 1) Microstructural alterations revealed with multimodal MRI scans including structure MRI (sMRI), resting state functional MRI (rs-fMRI), diffusion tensor imaging (DTI); 2) neuropsychological evaluation, including the World Health Organization-University of California-LosAngeles Auditory Verbal Learning Test (WHO-UCLA AVLT), Addenbrook’s cognitive examination-revised (ACE-R), mini-mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating scale (CDR). DISCUSSION: This study is to find out the neuroimaging biomarker and the changing laws of the marker during the progress of aMCI-ε4 to AD, and the final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of AD. TRIAL REGISTRATION: This study has been registered to ClinicalTrials.gov (NCT02225964, https://www.clinicaltrials.gov/) in August 24, 2014. BioMed Central 2016-05-12 /pmc/articles/PMC4866435/ /pubmed/27176479 http://dx.doi.org/10.1186/s12883-016-0587-2 Text en © Chen et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Chen, Guan-Qun
Sheng, Can
Li, Yu-Xia
Yu, Yang
Wang, Xiao-Ni
Sun, Yu
Li, Hong-Yan
Li, Xuan-Yu
Xie, Yun-Yan
Han, Ying
Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title_full Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title_fullStr Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title_full_unstemmed Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title_short Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial
title_sort neuroimaging basis in the conversion of amci patients with apoe-ε4 to ad: study protocol of a prospective diagnostic trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866435/
https://www.ncbi.nlm.nih.gov/pubmed/27176479
http://dx.doi.org/10.1186/s12883-016-0587-2
work_keys_str_mv AT chenguanqun neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT shengcan neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT liyuxia neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT yuyang neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT wangxiaoni neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT sunyu neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT lihongyan neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT lixuanyu neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT xieyunyan neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial
AT hanying neuroimagingbasisintheconversionofamcipatientswithapoee4toadstudyprotocolofaprospectivediagnostictrial